Cargando…

Human Target Attainment Probabilities for Delafloxacin against Escherichia coli and Pseudomonas aeruginosa

BACKGROUND: Delafloxacin (DLX) is a broad-spectrum fluoroquinolone antibiotic under FDA review for the treatment of ABSSSI. Previous studies determined DLX bacterial stasis and 1-log(10) bacterial reduction free AUC(0-24) / MIC (fAUC(0-24)/MIC) targets for Escherichia coli (EC) and Pseudomonas aerug...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoover, Randall, Marra, Andrea, Duffy, Erin, Cammarata, Sue K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631342/
http://dx.doi.org/10.1093/ofid/ofx163.1228